LDC1267

SKU: orb1223335

Description

LDC1267 is a potent and selective TAM kinase inhibitor. LDC1267 displays lower activity against Met, Aurora B, Lck, Src, and CDK8. LDC1267 markedly reduced murine mammary cancer and melanoma metastases dependent on NK cells. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo.

Key Properties

• CAS Number: 1361030-48-9
• MW: 560.55
• Purity: >98% (HPLC)
• Formula: C₃₀H₂₆F₂N₄O₅
• SMILES: c1(c(cc2c(c1)c(ccn2)Oc1ccc(cc1F)NC(=O)c1nn(cc1OCC)c1ccc(cc1C)F)OC)OC
• Target: PLK
• Solubility: DMSO : 50 mg/mL. 89.20 mM; H2O : < 0.1 mg/mL

Bioactivity

• In Vivo:
  Animal model: C57BL/6J wild type mice (8-12 weeks old syngeneic bearing B16F10 cells). Dosage: 20 mg/kg. Administration: Intraperitoneal injection; every 12 hours for 14 days. Result: Markedly reduced metastatic spreading of melanomas.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LDC1267 | LDC-1267 | LDC 1267

Quick Database Links

Gene Symbol

PLK